Lenvima

lenvatinib, the active ingredient in Lenvima, is a tyrosine kinase inhibitor presented as an oral tablet for oral use. It is indicated for several advanced solid tumours and is prescribed by oncologists for adult patients with specific cancer types. GNH USA supplies Lenvima as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres, pharmacies and clinics worldwide.

Lenvima targets multiple signalling pathways that drive tumour growth and angiogenesis, making it useful in several solid‑tumour indications. - Differentiated thyroid carcinoma: helps control disease progression in patients with radioactive iodine‑refractory disease. - Renal cell carcinoma: used in combination with everolimus to improve progression‑free survival. - Hepatocellular carcinoma: administered as first‑line therapy for unresectable disease. - Endometrial carcinoma: combined with pembrolizumab for advanced or recurrent cases.

Lenvima may cause a range of adverse reactions, which vary in frequency and severity.

Common Side Effects: - Hypertension: elevated blood pressure requiring monitoring. - Diarrhoea: may be mild to moderate. - Fatigue: persistent tiredness. - Nausea: occasional upset stomach. - Decreased appetite: reduced food intake. - Proteinuria: presence of protein in urine.

Serious or Rare Side Effects: - Hepatotoxicity: liver enzyme elevations or failure. - Cardiac dysfunction: reduced left‑ventricular ejection fraction. - Thromboembolic events: blood clots in veins or arteries. - Gastrointestinal perforation: rare but severe bowel injury. - Severe haemorrhage: uncontrolled bleeding. - Renal failure: impaired kidney function.

Before initiating Lenvima, clinicians should assess patient risk factors and monitor relevant parameters. - Blood pressure monitoring: check regularly and treat hypertension promptly. - Liver function tests: evaluate baseline and periodic hepatic enzymes. - Cardiac assessment: perform echocardiogram if history of heart disease. - Pregnancy risk: avoid use in pregnancy; discuss contraception. - Store at ambient temperature: keep below 25 °C, in original packaging, protected from moisture and light.

Lenvima can interact with several drug classes, influencing efficacy or safety.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole): may increase lenvatinib exposure. - Anticoagulants (e.g., warfarin): heightened risk of bleeding. - High‑dose aspirin or NSAIDs: increased gastrointestinal bleeding risk.

Moderate Interactions (Monitor Closely): - CYP3A4 inducers (e.g., rifampin): may reduce drug levels. - Diuretics: may exacerbate hypertension. - Hormonal contraceptives: potential reduced effectiveness.